首页 | 本学科首页   官方微博 | 高级检索  
     

金匮肾气丸合补中益气汤加减治疗绝经后骨质疏松症的疗效及对免疫炎症因子的调节作用
引用本文:安玉兰,曹昌霞,田玉梅,任磊,李志芳,程蓉,李海萍,吴焘,唐保明. 金匮肾气丸合补中益气汤加减治疗绝经后骨质疏松症的疗效及对免疫炎症因子的调节作用[J]. 中国实验方剂学杂志, 2021, 27(6): 69-75
作者姓名:安玉兰  曹昌霞  田玉梅  任磊  李志芳  程蓉  李海萍  吴焘  唐保明
作者单位:青海大学附属医院
基金项目:青海省医药卫生科技计划项目(2018-wjzdx-97)。
摘    要:目的:观察金匮肾气丸合补中益气汤加减治疗绝经后骨质疏松症(PMO)脾肾两虚证的临床疗效,对细胞免疫炎症因子的调节作用.方法 :将160例患者按随机数字表分为对照组和观察组,每组80例.两组患者均给予综合西医治疗措施,对照组口服壮骨止痛胶囊,4粒/次,3次/d;观察组口服金匮肾气丸联合补中益气汤治疗,1剂/d.两组均连续...

关 键 词:绝经后骨质疏松症  脾肾两虚证  金匮肾气丸  补中益气汤  骨密度  骨代谢指标  T细胞亚群  辅助性T细胞(Th)17  调节性T细胞(Treg)
收稿时间:2020-09-17

Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney
AN Yu-lan,CAO Chang-xi,TIAN Yu-mei,REN Lei,LI Zhi-fang,CHENG Rong,LI Hai-ping,WU Tao,TANG Bao-ming. Regulation Effect and Clinical Efficacy of Addition and Subtraction Therapy of Jinkui Shenqiwan Combined with Buzhong Yiqitang on Immune Inflammatory Factors of Patients with Postmenopausal Osteoporosis and Deficiency of Spleen and Kidney[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2021, 27(6): 69-75
Authors:AN Yu-lan  CAO Chang-xi  TIAN Yu-mei  REN Lei  LI Zhi-fang  CHENG Rong  LI Hai-ping  WU Tao  TANG Bao-ming
Affiliation:(Qinghai University Affiliated Hospital,Xining 810001,China)
Abstract:Objective:To observe the clinical efficacy of addition and subtraction therapy of Jinkui Shenqiwan combined with Buzhong Yiqitang to postmenopausal osteoporosis(PMO)with deficiency of spleen and kidney,and to investigate its regulation effect on immune inflammatory factors.Method:One hundred and sixty patients were randomly divided into observation group and control group,with 80 cases in each group.Both groups got comprehensive western medicine treatment measures.Patients in control group additionally got Zhuanggu Zhitong capsule,4 capsules/time,3 times/day.Patients in observation group additionally got addition and subtraction therapy of Jinkui Shenqiwan combined with Buzhong Yiqitang,1 dose/day.The treatment was continued for 24 weeks.Before and after treatment,lumbar L2-4 bone mineral density(BMD)was detected by Dual energy X-ray absorptiometry(DXA)and lumbar BMD was detected by quantitative CT(QCT).Scores of traditional Chinese medicine(TCM)syndromes and Chinese osteoporosis-targeted quality of life questionnaire(COQOL)were graded.Levels of Estradiol(E2),type Ⅰ procollagen amino terminal pro peptide(PINP),serum osteocalcin(OC),osteoprotegerin(OPG),type Ⅰ collagen cross-linked C-terminal peptide(S-CTX),tartrate resistant acid phosphatase(TRACP)and urinary pyridinoline(PYD)were detected.Levels of CD4+T cells,CD8+T cells,interleukin-17(IL-17),tumor necrosis factor-α(TNF-α),γ-interferon(IFN-γ)and interleukin-4(IL-4)were calculated.The proportion of T helper cell(Th)17 and regulatory T cell(Treg)in CD4+T cells was calculated.Besides,the safety was evaluated.Result:Bone density was detected by DXA in observation group,and its T-value and bone density detected by QCT were all higher than those in control group(P<0.01).After treatment,scores of TCM syndrome and COQOL were lower than those in control group(P<0.01).Levels of PINP,OC,S-CTX,TRACP and PYD/Cr were all lower than those in control group(P<0.01).Levels of OPG,CD8+and Treg were higher than those in control group(P<0.05),levels of Th17,Th17/Treg,CD4+/CD8+,IL-17,TNF-α and IFN-γ were lower(P<0.01),and levels of IL-4 and E2 were higher than those in control group(P<0.01).The clinical efficacy in observation group was better than that in control group(Z=2.103,P<0.05).Conclusion:On the basis of calcium and vitamin D supplementation,Jinkui Shenqiwan combined with Buzhong Yiqitang can improve levels of E2 and bone density,reduce clinical symptoms,improve quality of life,regulate bone metabolism index and immune inflammation reaction,with better clinical efficacy and safety.
Keywords:postmenopausal osteoporosis  deficiency of spleen and kidney  Jinkui Shenqiwan  Buzhong Yiqitang  bone mineral density  bone metabolism index  T cell subsets  T helper cell(Th)17  regulatory T cell(Treg)
本文献已被 维普 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号